B-cell lymphoma 2 (Bcl-2) has a dual function, acting both as an oncogene 20 and an anti-tumor gene. It is well known that Bcl-2 exerts its tumor promoting 21 function through the mitochondrial pathway. However, the mechanism by which 22 Bcl-2 suppresses tumor formation is not well understood. We have previously shown 23 that Bcl-2 inhibits cell cycle progression from the G 0 /G 1 to the S phase after serum 24 starvation, and that quiescent Bcl-2 expressing cells maintained a significant lower 25 level of mitochondrial reactive oxygen species (ROS) than the control cells. Based on 26 the fact that ROS mediate cell cycle progression, and are controlled by peroxisome 27 proliferator-activated receptor-γ co-activator 1α (PGC-1α), a key molecule induced by 28 . CC-BY 4.0 International license is made available under a
Introduction 39 B-cell lymphoma 2 (Bcl-2) has both pro-apoptotic and anti-apoptotic potentials. It 40 is well known that Bcl-2 protein is anchored to the mitochondrial outer membrane, 41 and antagonizes with the pro-apoptotic protein BAX by forming Bcl-2/BAX 42 heterodimers that control mitochondrial membrane permeability and promote 43 tumorigenesis (Hockenbery et al., 1990) . Bcl-2 acts as an anti-tumor gene in early 44 stage solid tumors, where it significantly reduces tumor incidence by regulating the 45 cell cycle (Vail et al., 2001; Murphy et al., 1999) . In vitro cell studies demonstrated 46 that the most pronounced cell cycle effect of Bcl-2 is delay of progression to S phase 47 from G0/G1 (Janumyan et al., 2008; Janumyan et al., 2003) , which has also been 48 confirmed in a Bcl-2 transgenic mouse model, where proliferation of lymphoid T cells 49 was restrained and tumor-associated morbidity was significantly decreased (Cheng et 50 al., 2004) . However, the signaling pathways by which Bcl-2 suppresses tumor 51 formation are not fully understood. 52 We have recently observed that quiescent Bcl-2 overexpressing cells maintain 53 less mitochondrial ROS (Reactive Oxygen Species) than control cells, elevation of 54 ROS accelerates cell cycle progression (unpublished data). These findings strongly 55 indicated that mitochondrial oxidative phosphorylation (OXPHOS) plays a key role in 56 the anti-proliferation function of Bcl-2. The most important factor identified to 57 modulate mitochondrial biogenesis and bioenergetics is peroxisome 58 proliferator-activated receptor-γ co-activator 1α (PGC-1α), which is predominantly 59 expressed in tissues with high energy demands, such as the heart, brain, and muscle 60 (McBride et al., 2006; Renee et al., 2008; Esterbauer et al., 1999) . As a co-activator, 61 PGC-1α interacts with a broad range of transcription factors and plays an important 62 role in glucose metabolism and prolonged starvation (Meirhaeghe et al., 2003; Lin et 63 al., 2005) . PGC-1α can translocate from the nucleus into the mitochondrial to 64 modulate mitochondrial function (Aquilano et al., 2010; Safdar et al., 2011; Smith et 65 al., 2013) . Furthermore, our recent findings uncovered that PGC-1α regulates the cell 66 cycle through ATP and ROS signals in fibroblast cells (Fu et al., 2016) . Therefore, we 67 proposed that PGC-1α might translocate into mitochondria to coordinate with Bcl-2's 68 tumor suppression functions through reducing ROS. 69 In this study, we investigated the relationship between Bcl-2 and PGC-1α. We 70 first establish Bcl-2 stable overexpressing cells and the control cells, synchronize 71 them in G 0 /G 1 phase using serum starvation (SS) or contact inhibition (CI), then 72 determine the effects of Bcl-2 over-expression or silencing on PGC-1α expression. 73 Similarly, Bcl-2 expression were detected in cells expressing high levels of PGC-1α 74 or after knockdown of PGC-1α. We found that PGC-1α positively correlates with 75 Bcl-2, Bcl-2 negatively responds to PGC-1α expression.
77

Results
78
PGC-1α expression increased in cells overexpressing Bcl-2 79
Mouse embryonic fibroblast NIH3T3 cells were transfected with Bcl-2 cloned in 80 a pBABEpuro plasmid (referred to as 3T3Bcl-2 in this paper). Cells transfected with 81 the empty vector served as the control (referred to as 3T3PB in this paper). We have 82 reported that PGC-1α inhibits the cell cycle progress, and Bcl-2 exerts its anti-tumor 83 function by delay cell cycle progress only at the G 0 /G 1 stage (Fu et al., 2016; Du et al., 84 2017; Janumyan et al., 2008) . Therefore, here, we first synchronize cells at the G 0 /G 1 85 stage by serum starvation, then compare PGC-1α expression in 3T3Bcl-2 cells with 86 3T3PB cells. Our cell cycle profiles showed that both 3T3PB and 3T3Bcl-2 were 87 arrested successfully in G 0 /G 1 phase, the proportion of cells in S phase dropped from 88 ~20% (normal growing, NG) to less than 3% (serum starved, SS) for both cells (Fig. 89 1A and 1B). We also observed a significant elevation in p27 levels in SS3T3Bcl-2 90 cells, confirming that Bcl-2 function as tumor-repressive gene through upregulating 91 p27 ( Fig. 1C and 1D ). At this stage, PGC-1α expression was clearly increased in 92 SS3T3Bcl-2 comparing with NG3T3Bcl-2 cells, while there was no significant 93 difference between control cells SS3T3PB and NG3T3PB ( Fig. 1C and 1E ). This 94 result suggests that PGC-1α expression associates with Bcl-2 after serum depletion.
96
To avoid experimental method bias, the results were verified in cells arrested by 97 contact inhibition (CI). Consistent with the results from the SS method ( Fig. 1 ), both 98 3T3PB and 3T3Bcl-2 cells were arrested in G 0 /G 1 phase (CI3T3PB and CI3T3Bcl-2, 99 respectively) ( Fig. 2A and 2B ), PGC-1α and p27 expression increased significantly in Western blotting analysis showed that Bcl-2 expression was significantly increased 137 after knockdown of PGC-1α ( Fig. 5C ). Based on these results and those shown in 138 Figure 4 , we conclude that Bcl-2 is negatively regulated by PGC-1α. was elevated as well in arrested Bcl-2 overexpressing cells but not in control cells 186 ( Fig. 1 and 2 ), suggesting a relationship between PGC-1α and Bcl-2. We hypothesized 187 that Bcl-2 may recruit and rely on PGC-1α to reduce ROS, which mediated cell cycle 188 as a critical signal. To test this possibility, Bcl-2 knockdown by siRNA was performed, 189 and as we expected, PGC-1α expression was correspondingly decreased (Fig.3) . 190 Together with the facts that PGC-1α regulates mitochondrial function to eliminate 191 ROS, and arrested Bcl-2 cells contain less ROS, these results suggest that Bcl-2 might 192 recruit PGC-1α to reduce ROS levels and block cell cycle progression. 193 To further clarify the relationship between Bcl-2 and PGC-1α, we investigated the 194 influence of PGC-1α knockdown on Bcl-2 expression. Endogenous expression of 195 PGC-1α is low in normal growing 3T3Bcl-2 and control cells (Fig. 1C, Fig. 2C ), and 196 we failed to over-express PGC-1α in Bcl-2 cells for unknown reasons; thus human 197 glioma U251 cells with high expression of endogenous PGC-1α were chosen to 198 perform the experiments. Fig. 5 shows that Bcl-2 expression was upregulated after 199 PGC-1α was successfully silenced. Consistent with this result, Bcl-2 was upregulated 200 following PGC-1α downregulation during the SS treatment (Fig. 4) . These results The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It . https://doi.org/10.1101/111567 doi: bioRxiv preprint
Figure legends
